SAT-502 Clinical Hypothyroidism Associated with Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma: A Novel Adverse Effect of Peptide Receptor Radionuclide Therapy

Background: Peptide receptor radionuclide therapy (PRRT) is a relatively novel, emerging therapy for the treatment of metastatic pheochromocytoma and paraganglioma (PPGL). Lutetium 177 ((177)Lu)-DOTATATE (Lutathera ®) is a form of PRRT that is currently being evaluated for its treatment efficacy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gubbi, Sriram, Al-Jundi, Mohammad, Jha, Abhishek, Knue, Marianne, Zou, Joy, Rivero, Jaydira Del, Turkbey, Baris, Carrasquillo, Jorge A, Pacak, Karel, Klubo-Gwiezdzinska, Joanna, Lin, Frank I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209344/
http://dx.doi.org/10.1210/jendso/bvaa046.1349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209344/
http://dx.doi.org/10.1210/jendso/bvaa046.1349

Ejemplares similares